Reviews on covid drug development

Aus coViki
Wechseln zu: Navigation, Suche
  • GET 2020. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases Extract
  • GET ä. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods Extract
  • GET ä. D3Targets-2019-nCoV: a webserver for predicting drug targets and for multi-target and multi-site based virtual screening against COVID-19 Extract
  • GET 2020. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus Extract
  • GET 2020. Potential Treatments for COVID-19; a Narrative Literature Review Extract
  • GET 2020. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19) Extract
  • GET 2020. Coronavirus Pandemic-Therapy and Vaccines Extract
  • GET 2020. Drug treatment options for the 2019-new coronavirus (2019-nCoV) Extract
  • GET ä. Current status of potential therapeutic candidates for the COVID-19 crisis Extract
  • GET ä. Seeking and destroying the evils from the inside-translating cancer immunity to fight COVID-19 Extract
  • GET 2020. Impact of glycoscience in fighting Covid-19. Extract
  • GET 2020. A Review on Applications of Computational Methods in Drug Screening and Design Extract
  • GET 2020. Study of combining virtual screening and antiviral treatments of the Sars-CoV-2 (Covid-19) Extract
  • GET ä. Current development of COVID-19 diagnostics, vaccines and therapeutics Extract
GET 2020. The CoV-2 outbreak: how hematologists could help to fight Covid-19 Extract
idiotic title; reviews many immunopharmocological targets
  • GET 2020. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2 Extract
  • GET ä. Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model Extract
  • GET 2020. COVID-19: Immunology and treatment options Extract
  • GET ä. Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model Extract
  • GET 2020. Coronaviruses: A patent dataset report for research and development (R&D) analysis Extract
  • GET ä. Emerging Therapeutic Strategies for COVID-19 patients Extract
  • GET 2020. Treatment of SARS-CoV-2: How far have we reached? Extract
  • GET 2020. Discovering drugs to treat coronavirus disease 2019 (COVID-19) Extract
  • GET ä. Advance of promising targets and agents against COVID-19 in China Extract
  • GET ä. Deja vu: Stimulating open drug discovery for SARS-CoV-2 Extract
  • GET ä. Boosting the arsenal against COVID-19 through computational drug repurposing Extract
  • GET 2020. Medication for COVID-19-an Overview of Approaches Currently Under Study Extract
  • GET 2020. Medical treatment options for COVID-19 Extract
  • GET 2020. Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol Extract
  • GET 2020. Will plant-made biopharmaceuticals play a role in the fight against COVID-19? Extract
  • GET 2020. Perspectives for repurposing drugs for the coronavirus disease 2019 Extract
  • GET 2020. Tracking the impact of interventions against COVID-19 in absence of extensive testing Extract
  • GET 2020. Drug targets for corona virus: A systematic review Extract
  • GET ä. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status Extract
  • GET 2020. Update on treatment of COVID-19: ongoing studies between promising and disappointing results Extract
  • GET ä. SARS-Cov-2 infection: response of human immune system and possible implications for the rapid test and treatment Extract
  • GET ä. Drug repositioning is an alternative for the treatment of coronavirus COVID-19 Extract
  • GET ä. The Possible of Immunotherapy for COVID-19: a Systematic Review Extract
  • GET ä. Perspectives: potential therapeutic options for SARS-CoV-2 patients based on feline infectious peritonitis strategies: central nervous system invasion and drug coverage Extract
  • GET ä. Combating Devastating COVID -19 by Drug Repurposing Extract
  • GET 2020. COVID-19 Drug Discovery Using Intensive Approaches Extract
  • GET ä. Coronavirus disease 2019 (COVID-19): current status and future perspectives Extract
  • GET ä. A Community Letter Regarding Sharing Biomolecular Simulation Data for COVID-19 Extract
  • GET ä. Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study Extract
  • GET 2020. Potential therapeutic agents against COVID-19: What we know so far Extract
  • GET ä. Pharmacologic Therapy for COVID-19 Infection Extract
  • GET 2020. Pharmacological Therapeutics Targeting RNA-Dependent RNA Polymerase, Proteinase and Spike Protein: From Mechanistic Studies to Clinical Trials for COVID-19 Extract
  • GET ä. Treatment options for COVID-19: The reality and challenges Extract
  • GET 2020. Current Drugs with Potential for Treatment of COVID-19: A Literature Review Extract
  • GET ä. CNS penetration of potential anti-COVID-19 drugs Extract
  • GET 2020. Delivering Benefits at Speed Through Real-World Repurposing of Off-Patent Drugs: The COVID-19 Pandemic as a Case in Point Extract
  • GET 2020. Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome Extract
  • GET 2020. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics Extract
  • GET 2020. Is Immuno-modulation the Key to COVID-19 Pandemic? Extract
  • GET 2020. Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID?19: initial assessment Extract
  • GET ä. COVID-19: Therapeutics and Their Toxicities Extract
  • GET 2020. Potential interventions for novel coronavirus in China: A systematic review Extract
  • GET ä. Structural elucidation of SARS-CoV-2 vital proteins: Computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase Extract
  • GET 2020. Reducing mortality from 2019-nCoV: host-directed therapies should be an option Extract
  • GET 2020. COVID-19 therapeutic options for patients with kidney disease Extract
  • GET 2020. Immunosuppression for hyperinflammation in COVID-19: a double-edged sword? Extract
  • GET 2020. Flooded by the torrent: the COVID-19 drug pipeline Extract
  • GET ä. Use of antiviral drugs to reduce COVID-19 transmission Extract
  • GET ä. Plea for multitargeted interventions for severe COVID-19 Extract
  • GET 2020. COVID-19: combining antiviral and anti-inflammatory treatments Extract
  • GET 2020. Preventing COVID-19-induced pneumonia with anticytokine therapy Extract
  • GET 2020. In silico studies on therapeutic agents for COVID-19: Drug repurposing approach Extract
  • GET 2020. Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection Extract
  • GET 2020. Target Virus or Target Ourselves for COVID-19 Drugs Discovery?-Lessons learned from anti-influenzas virus therapies Extract
  • GET 2020. Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines Extract
  • A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing
  • GET 2020. Emerging prophylaxis strategies against COVID-19 Extract
  • GET ä. COVID-19: risk for cytokine targeting in chronic inflammatory diseases? Extract
  • GET 2020. Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options Extract
  • GET 2020. Antibody-based therapies for COVID-19: Can Europe move faster? Extract
  • GET ä. Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis Extract
  • GET 2020. Pandemic responses: Planning to neutralize SARS-CoV-2 and prepare for future outbreaks Extract
  • GET ä. Candidate drugs against SARS-CoV-2 and COVID-19 Extract
  • GET 2020. COVID-19: A Brief Overview of the Discovery Clinical Trial Extract
  • GET ä. Current targeted therapeutics against COVID-19: based on first-line experience in china Extract
  • GET 2020. Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development Extract
  • GET 2020. Clinical trials on drug repositioning for COVID-19 treatment Extract
  • GET ä. Coronavirus in Hematologic Malignancies: Targeting Molecules Beyond the Angiotensin-Converting Enzyme 2 (ACE2) Wall in COVID-19 Extract
  • GET 2020. A short review on antibody therapy for COVID-19 Extract
  • GET ä. COVID-19 Outbreak: an Update on Therapeutic Options Extract
  • GET ä. Clinical trials for the treatment of Coronavirus disease 2019 (COVID-19): A rapid response to urgent need Extract
  • GET ä. SARS-CoV-2 and COVID-19: What are our options? Where should we focus our attention on to find new drugs and strategies? Extract
  • GET ä. COVID-19: A promising cure for the global panic Extract
  • GET 2020. Antiviral treatment of COVID-19 Extract
  • GET ä. Potential applications of plant biotechnology against SARS-CoV-2 Extract
  • GET ä. Ongoing Clinical Trials for the Management of the COVID-19 Pandemic Extract
  • GET 2020. Drug trials under way Extract
  • GET ä. Covid-19 ? The Search for Effective Therapy Extract
  • GET 2020. Novel Coronavirus Disease (COVID-19): The Need for Immunoprevention at Industrial Scale Extract
  • GET 2020. On Facing the SARS-CoV-2 (COVID-19) with Combination of Nanomaterials and Medicine: Possible Strategies and First Challenges Extract
  • GET 2020. Can Nanotechnology and Materials Science Help the Fight against SARS-CoV-2? Extract
  • GET 2020. Are there any Therapeutic Options Currently Available for Wuhan Coronavirus? Extract
GET ä. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions Extract
  • GET 2020. Covid-19: what treatments are being investigated? Extract
  • GET 2020. Dosing will be a key success factor in repurposing antivirals for COVID-19 Extract
  • GET 2020. Challenges in Drug Development Posed by the COVID-19 Pandemic: An Opportunity for Clinical Pharmacology Extract
  • GET 2020. Potential Therapeutic Targets and Promising Drugs for Combating SARS-CoV-2 Extract
GET 2020. A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development IUPHAR Review 29 Extract
  • GET 2020. Current pharmacological treatments for COVID-19: What s next? Extract
  • GET 2020. Cytokine Storm Drugs Move from CAR T to COVID-19 Extract
  • GET 2020. Harnessing CAR T-cell Insights to Develop Treatments for Hyperinflammatory Responses in Patients with COVID-19 Extract
  • GET 2020. Respiratory conditions in coronavirus disease 2019 (COVID-19): Important considerations regarding novel treatment strategies to reduce mortality Extract
GET 2020. Drug Development and Medicinal Chemistry Efforts toward SARS-Coronavirus and Covid-19 Therapeutics Extract
  • GET 2020. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs Extract
  • GET 2020. Covid-19: trials of four potential treatments to generate "robust data" of what works Extract
  • GET 2020. Updated Approaches against SARS-CoV-2 Extract
GET ä. Immunomodulatory therapy for the management of severe COVID-19 Beyond the anti-viral therapy: A comprehensive review Extract
GET ä. Seven recommendations to rescue the patients and reduce the mortality from COVID-19 infection: An immunological point of view Extract
  • GET 2020. Thoughts on What Chemists Can Contribute to Fighting SARS-CoV-2 - A Short Note on Hand Sanitizers, Drug Candidates and Outreach Extract
  • GET ä. Rheumatologists? perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets Extract
  • GET 2020. Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19 Extract
  • GET 2020. COVID-19 Respiratory Failure: Targeting Inflammation on VV-ECMO Support Extract
  • GET ä. Insights from nanomedicine into chloroquine efficacy against COVID-19 Extract
  • GET ä. Cytokine storm intervention in the early stages of COVID-19 pneumonia Extract
  • GET 2020. Antiviral Agents: Discovery to Resistance Extract
  • GET 2020. In Silico Discovery of Candidate Drugs against Covid-19 Extract
  • GET 2020. Repurposing Antiviral Protease Inhibitors Using Extracellular Vesicles for Potential Therapy of COVID-19 Extract
  • GET 2020. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China Extract
  • GET 2020. Molecular Investigation of SARS-CoV-2 Proteins and Their Interactions with Antiviral Drugs Extract
  • GET 2020. Effective Chemicals against Novel Coronavirus (COVID-19) in China Extract
  • GET 2020. Could host cell receptor alteration prevent SARS-CoV-2 viral entry? - Hype or hope Extract
  • GET 2020. Quadruple therapy for asymptomatic COVID-19 infection patients Extract
  • GET ä. COVID?19 treatment by repurposing drugs until the vaccine is in sight Extract
  • GET ä. COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus Extract
  • GET 2020. Peptide-like and small-molecule inhibitors against Covid-19 Extract
  • GET 2020. Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future Extract
  • GET 2020. SARS-CoV-2 & Covid-19: Key-Roles of the Renin-Angiotensin System / Vitamin D Impacting Drug and Vaccine Developments Extract
  • GET 2020. Existing bitter medicines for fighting 2019-nCoV-associated infectious diseases Extract
  • GET 2020. Knowledge-based structural models of SARS-CoV-2 proteins and their complexes with potential drugs Extract
  • GET ä. Comments on Zhang et al: Clinical trial analysis of 2019?nCoV therapy registered in China Extract
  • GET ä. Harnessing the immune system via Fc?R function in immune therapy: a pathway to next?gen mAbs Extract
  • GET ä. Immunomodulation in COVID-19 Extract
  • GET 2020. Drug Evaluation during the Covid-19 Pandemic Extract
  • GET 2020. Drug repurposing in the era of COVID-19: a call for leadership and government investment Extract
  • GET 2020. The COVID-19 vaccine development landscape Extract
GET 2020. Application of nanomaterials in treatment, anti-infection and detection of coronaviruses Extract
GET 2020. A Chemographic Audit of anti-Coronavirus Structure-Activity Information from Public Databases (ChEMBL) Extract
GET 2020. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing Extract
  • GET 2020. Coordinating the COVID-19 pipeline Extract
  • GET 2020. Therapeutic options for the 2019 novel coronavirus (2019-nCoV) Extract
  • GET 2020. Some drugs for COVID-19 Extract
  • GET 2020. Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics Extract
  • GET 2020. Finding Effective Treatments for COVID-19: Scientific Integrity and Public Confidence in a Time of Crisis Extract
  • GET 2020. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review Extract
  • GET 2020. Artificial intelligence and machine learning to fight COVID-19 Extract
  • GET ä. Controversial treatments: An updated understanding of the coronavirus disease 2019 Extract
  • GET 2020. Evaluation of Antiviral Therapies for Coronavirus Disease 2019 (COVID-19) Pneumonia in Shanghai, China Extract
  • GET ä. Clinical trial analysis of 2019?nCoV therapy registered in China Extract
  • GET 2020. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019 Extract
  • GET ä. COVID-19 and the Rationale for Pharmacotherapy: A South African Perspective Extract
  • GET 2020. Potential antiviral therapeutics for 2019 Novel Coronavirus Extract
  • GET 2020. Pharmacotherapeutics for the new coronavirus pneumonia Extract
  • GET 2020. Pharmacotherapeutic about the new coronavirus pneumonia Extract
  • GET ä. Antibody therapies for the treatment of COVID-19 Extract
  • GET 2020. Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department Extract
  • GET 2020. Biological Product Development Strategies for Prevention and Treatment of Coronavirus Disease 2019 Extract
  • GET 2020. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions Extract
  • GET 2020. Frontiers in antiviral therapy and immunotherapy Extract
  • GET 2020. Embracing the Landscape of Therapeutics Extract
  • GET ä. Drug repurposing strategies for COVID-19 Extract
  • GET ä. COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus Extract
  • GET 2020. Using integrated computational approaches to identify safe and rapid treatment for SARS-CoV-2 Extract
  • GET ä. Testing COVID-19 therapies to prevent progression of mild disease Extract
  • GET 2020. Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach Extract
  • GET 2020. Structure-Based Stabilization of Non-native Protein?Protein Interactions of Coronavirus Nucleocapsid Proteins in Antiviral Drug Design Extract
  • GET 2020. Discovery and development of safe-in-man broad-spectrum antiviral agents Extract
  • GET 2020. Molecular docking and dynamic simulations for antiviral compounds against SARS-CoV-2: A computational study. Extract
  • GET 2017. (+)Novel translational approaches to the search for precision therapies for acute respiratory distress syndrome Extract
  • GET 2020. Computational screening of antagonists against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking. Extract
  • GET 2020. Can graphene take part in the fight against COVID-19? Extract
  • GET 2020. A short review on antibody therapy for COVID-19 Extract
  • GET ä. Developing therapeutic monoclonal antibodies at pandemic pace Extract
  • GET 2020. Repurposing approved drugs on the pathway to novel therapies Extract
  • GET 2020. A new paradigm for drug development Extract
  • GET 2020. An overview of functional nanoparticles as novel emerging antiviral therapeutic agents Extract
  • GET ä. Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof) Extract
  • GET 2020. Covid-19 and drug therapy, what we learned. Extract
  • GET 2020. High throughput virtual screening reveals SARS-CoV-2 multi-target binding natural compounds to lead instant therapy for COVID-19 treatment. Extract
  • GET 2020. A large number of COVID-19 interventional clinical trials were registered soon after the pandemic onset: a descriptive analysis. Extract
  • GET 2020. The 4 D's of Pellagra and Progress. Extract
  • GET 2020. Trials and tribulations: so many potential treatments, so few answers. Extract
  • GET 2020. Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review. Extract
  • GET 2020. The Ethics of COVID-19 Clinical Trials: New Considerations in a Controversial Area. Extract
  • GET 2020. A global treatments for coronaviruses including COVID-19. Extract
  • GET 2020. Deep Learning Based Drug Screening for Novel Coronavirus 2019-nCov. Extract
  • GET 2020. S1 Subunit and Host Proteases as Potential Therapeutic Avenues for the Treatment of COVID-19. Extract
  • GET 2020. Clinical trials for coronavirus disease 2019: What is being evaluated and what is not. Extract
  • GET 2020. Anti COVID-19 Drugs: Need for More Clinical Evidence and Global Action. Extract
  • GET 2020. The preventive strategy for pandemics in the elderly is to collect in advance samples & data to counteract chronic inflammation (inflammaging). Extract
  • GET 2020. Clinical trials: management of investigational products during the coronavirus (COVID-19) pandemic. Extract
  • GET 2020. COVID-19 and Other Pandemics: How Might They Be Prevented? Extract
  • GET 2020. Toward Nanotechnology-Enabled Approaches against the COVID-19 Pandemic. Extract
  • GET 2020. Research Progress of Drug Treatment in Novel Coronavirus Pneumonia. Extract
  • GET 2020. Rigorous Randomized Controlled Trial Implementation in the Era of COVID-19. Extract
  • GET 2020. When the Others Become Us: A Chemist's Perspective of the COVID-19 Outbreak in Italy. Extract
  • GET 2020. Proposed Intranasal Route for Drug Administration in the Management of Central Nervous System Manifestations of COVID-19. Extract
  • GET 2020. Artificial intelligence approach fighting COVID-19 with repurposing drugs. Extract
  • GET 2020. Emerging pharmacotherapies for COVID-19. Extract
  • GET 2020. Employing drug delivery strategies to create safe and effective pharmaceuticals for COVID-19. Extract
  • GET 2020. The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review. Extract
  • GET 2020. Computation screening of narcissoside a glycosyloxyflavone for potential novel coronavirus 2019 (COVID-19) inhibitor. Extract
  • GET 2020. Interactions of recommended COVID-19 drugs with commonly used psychotropics. Extract
  • GET 2020. Effectiveness and safety of available treatments for COVID-19 during pregnancy: a critical review. Extract
  • GET 2020. In Silico Exploration of the Molecular Mechanism of Clinically Oriented Drugs for Possibly Inhibiting SARS-CoV-2's Main Protease. Extract
  • GET 2020. Current regulatory approaches for accessing potential COVID-19 therapies. Extract
  • GET 2020. Targeting SARS-CoV-2: Novel Source of Antiviral Compound(s) against COVID-19? Extract
  • GET 2020. COVID-19 and off label use of drugs: an ethical viewpoint. Extract
  • GET 2020. Comprehensive overview of COVID-19 clinical trials. Extract
  • GET 2020. Treatment options in people with COVID19: Selecting the best armamentarium against the novel virus. Extract
  • GET 2020. The COVID-19 chemoprophylactic conundrum: Are we limiting available resources? Extract
GET 2020. The G-Quadruplex/Helicase World as a Potential Antiviral Approach Against COVID-19. Extract
GET 2020. Physicochemical properties of SARS-CoV-2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality control. Extract
  • GET 2020. A brief note on randomized controlled trials and compassionate/off-label use of drugs in the early phases of the COVID-19 pandemic. Extract
  • GET 2020. Pharmacological treatment of COVID-19: lights and shadows. Extract
  • GET 2020. An Update on Current Therapeutic Drugs Treating COVID-19. Extract
  • GET 2020. A Precision Medicine Approach to SARS-CoV-2 Pandemic Management. Extract
  • GET 2020. Multigroup, Adaptively Randomized Trials Are Advantageous for Comparing Coronavirus Disease 2019 (COVID-19) Interventions. Extract
  • GET 2020. The quality of the reported sample size calculation in clinical trials on COVID-19 patients indexed in PubMed. Extract
  • GET 2020. Natural experiment concept to accelerate the Re-purposing of existing therapeutics for Covid-19. Extract
  • GET 2020. Molecular structure analyses suggest strategies to therapeutically target SARS-CoV-2. Extract
  • GET 2020. Empirical Treatment and Prevention of COVID-19. Extract
  • GET 2020. Clinical trials for COVID-19 should include sex as a variable. Extract
  • GET 2020. Nanomaterials and Nanotechnology-Associated Innovations against Viral Infections with a Focus on Coronaviruses. Extract
  • GET 2020. Palliativ farmakologisk behandling vid svar covid-19. Extract
  • GET 2020. Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets. Extract
  • GET 2020. Towards Precision Medicine: Inclusion of Sex and Gender Aspects in COVID-19 Clinical Studies-Acting Now before It Is Too Late-A Joint Call for Action. Extract
  • GET 2020. Nicotinamide Riboside-The Current State of Research and Therapeutic Uses. Extract
  • GET 2020. Investigation of Some Antiviral N-Heterocycles as COVID 19 Drug: Molecular Docking and DFT Calculations. Extract
  • GET 2020. Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases. Extract
  • GET 2020. Emergence of novel coronavirus and progress toward treatment and vaccine. Extract
  • GET 2020. Current Perspective of Antiviral Strategies against COVID-19. Extract
  • GET 2020. Understanding Observational Treatment Comparisons in the Setting of Coronavirus Disease 2019 (COVID-19). Extract
  • GET 2020. Reply to Kesici et al. and Zeng et al.: Blocking the virus and reducing the inflammatory damage in COVID-19. Extract
  • GET 2020. How to Rapidly Determine First-in-Children Dosing for COVID-19 Therapeutics. Extract
  • GET 2020. How to Discover Antiviral Drugs Quickly. Extract
  • GET 2020. Spiky Nanostructures with Geometry-matching Topography for Virus Inhibition. Extract
  • GET 2020. Reporter Replicons for Antiviral Drug Discovery against Positive Single-Stranded RNA Viruses. Extract
  • GET 2020. Pandemic could add noise to clinical trial data. Extract
  • GET 2020. COVID-19: Main therapeutic options. Extract
  • GET 2020. The Rationale for Potential Pharmacotherapy of COVID-19. Extract
  • GET 2020. Challenges at the Time of COVID-19: Opportunities and Innovations in Antivirals from Nature. Extract
  • GET 2020. Ethics of controlled human infection to address COVID-19. Extract
  • GET 2020. Aggregating data from COVID-19 trials. Extract
  • GET 2020. A snapshot of the ongoing clinical research on COVID-19. Extract
  • GET 2020. The role of growth factor receptors in viral infections: An opportunity for drug repurposing against emerging viral diseases such as COVID-19? Extract
  • GET 2020. The Current and Future State of Vaccines, Antivirals and Gene Therapies Against Emerging Coronaviruses. Extract
  • GET 2020. Cardiovascular Impairment in COVID-19: Learning From Current Options for Cardiovascular Anti-Inflammatory Therapy. Extract
  • GET 2020. [Pharmacotherapeutics for the New Coronavirus Pneumonia]. Extract
  • GET 2020. Important interactions of immunosuppressants with experimental therapies for novel coronavirus disease (COVID-19): how to act. Extract
  • GET 2020. [Pharmaceutical care for severe and critically ill patients with COVID-19]. Extract
GET 2020. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Extract
  • GET 2020. Potential pharmacological agents for COVID-19. Extract
  • GET 2020. Targeting SARS-CoV-2 Receptors as a Means for Reducing Infectivity and Improving Antiviral and Immune Response: An Algorithm-based Method For Overcoming Resistance To Antiviral Agents. Extract
  • GET 2020. Ribosomal proteins as a possible tool for blocking SARS-COV 2 virus replication for a potential prospective treatment. Extract
  • GET 2020. COVID-19 patients benefit from early antiviral treatment: a comparative, retrospective study. Extract
  • GET 2020. Need for Transparency and Reliable Evidence in Emergency Use Authorizations for Coronavirus Disease 2019 (COVID-19) Therapies. Extract
  • GET 2020. Potential pharmacological perspectives for the treatment/prevention of the SARS-COV-2 infection in opioid dependent patients. Extract
  • GET 2020. Repurposing current therapeutics for treating COVID-19: A vital role of prescription records data mining. Extract
GET 2020. Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity. Extract
  • GET 2020. The race is on for antibodies that stop the new coronavirus. Extract
  • GET 2020. Combination prevention for COVID-19. Extract
  • GET 2020. Reducing transmission of SARS-CoV-2. Extract
  • GET 2020. Rapid repurposing of drugs for COVID-19. Extract
  • GET 2020. NIH organizes hunt for drugs. Extract
  • GET 2020. Repurposing approved drugs as inhibitors of SARS-CoV-2 S-protein from molecular modeling and virtual screening. Extract
  • GET 2020. Evaluation of potential therapeutic options for COVID-19. Extract
  • GET 2020. Antivirals for COVID-19. Extract
  • GET 2020. Ratcheting down the virulence of SARS-CoV-2 in the COVID-19 pandemic. Extract
  • GET 2020. Potential Unconventional Medicines for the Treatment of SARS-CoV-2. Extract
  • GET 2020. Intuitive Global Insight Into COVID-19 Clinical Research Activities-The "COVID-19 Map of Hope". Extract
  • GET 2020. A perspective on modern advances for COVID-19 (SARS-CoV-2) therapeutics. Extract
  • GET 2020. Food protein-derived antihypertensive peptides in the COVID-19 pandemic: friends of foes? Extract
  • GET 2020. Therapeutic Temperature Modulation for a Critically Ill Patient with COVID-19. Extract
  • GET 2020. [Farmakoterapias lehetosegek SARS-CoV-2-fertozes/COVID-19-betegseg eseten] Extract
  • GET 2020. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research. Extract
  • GET 2020. Treatment considerations for coronavirus (COVID-19). Extract
  • GET 2020. COVID-19: Gene Transfer to the Rescue? Extract
  • GET 2020. The Impact of the COVID-19 Pandemic on the Biotech Industry. Extract
  • GET 2020. A Message to Our Community in the Midst of the COVID-19 Pandemic. Extract
  • GET 2020. Can 3D printing of oral drugs help fight the current COVID-19 pandemic (and similar crisis in the future)? Extract
  • GET 2020. An up-to-date overview of computational polypharmacology in modern drug discovery. Extract
  • GET 2020. Comprehensive analysis of drugs to treat SARSCoV2 infection: Mechanistic insights into current COVID19 therapies (Review). Extract
  • GET 2020. Treatments in the COVID-19 pandemic: an update on clinical trials. Extract
  • GET 2020. A Call for Pediatric COVID-19 Clinical Trials. Extract
  • GET 2020. COVID-19 pandemic: what can pharmaceutical formulation and drug delivery experts offer? Extract
  • GET 2020. Recent advances of therapeutic targets and potential drugs of COVID-19. Extract
  • GET 2020. The post-lockdown period should be used to acquire effective therapies for future resurgence in SARS-Cov-2 infections. Extract
  • GET 2020. COVID-19Clinical trials: quality matters more than quantity. Extract
  • GET 2020. Randomized Clinical Trials and COVID-19: Managing Expectations. Extract
  • GET 2020. Using Controlled Trials to Resolve Key Unknowns About Policy During the COVID-19 Pandemic. Extract
  • GET 2020. The coronavirus outbreak could make it quicker and easier to trial drugs. Extract
GET 2020. CRISPR tool scales up to interrogate a huge line-up of viral suspects. Extract
  • GET 2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets. Extract
  • GET 2020. The sprint to solve coronavirus protein structures - and disarm them with drugs. Extract
  • GET 2020. Dozens of coronavirus drugs are in development - what happens next? Extract
  • GET 2020. Coronavirus drugs trials must get bigger and more collaborative. Extract
  • GET 2020. Molecular docking, simulation and MM-PBSA studies of nigella sativa compounds: a computational quest to identify potential natural antiviral for COVID-19 treatment. Extract
  • GET 2020. Biggest COVID-19 trial tests repurposed drugs first. Extract
  • GET 2020. Drug researchers pursue new lines of attack against COVID-19. Extract
  • GET 2020. Biotech companies prepare for COVID-19 downturn. Extract
  • GET 2020. 15 drugs being tested to treat COVID-19 and how they would work. Extract
  • GET 2020. The pharmacological development of direct acting agents for emerging needed therapy against SARS-CoV-2. Extract
GET 2020. Virtual screening-driven drug discovery of SARS-CoV2 enzyme inhibitors targeting viral attachment, replication, post-translational modification and host immunity evasion infection mechanisms. Extract
GET 2020. Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools. Extract
  • GET 2020. Research towards treating COVID-19. Extract
  • GET 2020. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19). Extract
  • GET 2020. Lung tissue distribution of drugs as a key factor for COVID-19 treatment. Extract
  • GET 2020. COVID-19: Drug targets and potential treatments. Extract
  • GET 2020. Time to Step Up: A Call to Action For the Clinical and Quantitative Pharmacology Community to Accelerate Therapeutics for COVID-19. Extract
  • GET 2020. A Real-World Evidence Framework for Optimising Dosing in All Patients with COVID-19. Extract
  • GET 2020. Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics. Extract
  • GET 2020. COVID-19: A Personalized Cardiometabolic Approach for Reducing Complications and Costs. The Role of Aging beyond Topics. Extract
GET 2020. Ligand-centered assessment of SARS-CoV-2 drug target models in the Protein Data Bank. Extract
GET 2020. iBioProVis: Interactive Visualization and Analysis of Compound Bioactivity Space. Extract
  • GET 2020. Treatments for COVID-19: emerging drugs against the coronavirus. Extract
  • GET 2020. Medicines for the Treatment Of COVID-19: Awaiting the Evidence. Extract
  • GET 2020. Drugs being investigated for children with COVID-19. Extract
  • GET 2020. RECOVERY trial: the UK covid-19 study resetting expectations for clinical trials. Extract
  • GET 2020. Accelerating drug development through repurposed FDA approved drugs for COVID-19: speed is important, not haste. Extract
  • GET 2020. Importance of Pediatric Inclusion in COVID-19 Therapeutic Trials. Extract
  • GET 2020. The World of Clinical Trial Development Post-Covid-19: Lessons Learned from a Global Pandemic. Extract
  • GET 2020. In Reply: COVID-19: An Argument for Rapid Access to Laboratory Data Warehouses. Extract
  • GET 2020. Drug Repurposing for COVID-19: Ethical Considerations and Roadmaps. Extract
  • GET 2020. Coronavirus Disease (COVID-19) Pandemic: A Race Against Time. Extract
  • GET 2020. Exclusion of Pregnant Women from Clinical Trials during the Coronavirus Disease 2019 Pandemic: A Review of International Registries. Extract
  • GET 2020. Emerging therapies for COVID-19 pneumonia. Extract
  • GET 2020. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review. Extract
  • GET 2020. Old and re-purposed drugs for the treatment of COVID-19. Extract
  • GET 2020. How could artificial intelligence aid in the fight against coronavirus? Extract
  • GET 2020. The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: 'Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology pracitioners from India' by Gupta et al and 'Antirheumatic agents in covid-19: is IL-6 the right target?' by Capeechi et al. Extract
  • GET 2020. COVID-19 breakthroughs: separating fact from fiction. Extract
  • GET 2020. Optimizing COVID-19 Candidate Therapeutics: Thinking Without Borders. Extract
  • GET 2020. Paediatric treatment trials for COVID-19 are an ethical imperative. Extract
  • GET 2020. Perspective on the COVID-19 Coronavirus Outbreak. Extract
  • GET 2020. A Generic Computer-Assisted Four-Pronged Approach for the Management of Emerging Global Pathogens: Some Comments on COVID-19. Extract
  • GET 2020. In vitro data of current therapies for SARS-CoV-2. Extract
  • GET 2020. Implications of the lack of a unified research project framework: an investigation into the registration of clinical trials of COVID-19. Extract
  • GET 2020. A call for the appropriate application of clinical pharmacological principles in the search for safe and efficacious COVID-19 (SARS-COV-2) treatments. Extract
  • GET 2020. Drug-Induced Liver Injury and COVID-19 Infection: The Rules Remain the Same. Extract
  • GET 2020. COVID-19 and toxicity from potential treatments: Panacea or poison. Extract
GET 2020. siRNA could be a potential therapy for COVID-19. Extract
  • GET 2020. Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery. Extract
  • GET 2020. COVID-19: An Update on Clinical Trials. Extract
  • GET 2020. Pandemic Best Regulatory Practices: An Urgent Need in the Covid-19 Pandemic. Extract
  • GET 2020. The need to implement non-industry COVID-19 clinical trials in non-high-income countries. Extract
  • GET 2020. COVID-19: A Defining Moment for Clinical Pharmacology? Extract
  • GET 2020. Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019. Extract
  • GET 2020. Minimum costs to manufacture new treatments for COVID-19. Extract
  • GET 2020. Intervencoes nao farmacologicas para o enfrentamento a epidemia da COVID-19 no Brasil. Extract
  • GET 2020. Consider pregnancy in COVID-19 therapeutic drug and vaccine trials. Extract
  • GET 2020. Three novel prevention, diagnostic, and treatment options for COVID-19 urgently necessitating controlled randomized trials. Extract
  • GET 2020. Virtual screening, ADME/Tox predictions and the drug repurposing concept for future use of old drugs against the COVID-19. Extract
  • GET 2020. Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements. Extract
  • GET 2020. A computational prediction of SARS-CoV-2 structural protein inhibitors from Azadirachta indica (Neem). Extract
  • GET 2020. State-of-the-art tools to identify druggable protein ligand of SARS-CoV-2. Extract
  • GET 2020. COVID-19 and picotechnology: Potential opportunities. Extract
  • GET 2020. A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19). Extract
  • GET 2020. Optimising effectiveness of health care and value of clinical trials in the COVID -19 outbreak. Extract
  • GET 2020. Demand for potentially hazardous COVID-19 treatments. Extract
  • GET 2020. ICER releases pricing models for potential COVID-19 treatments. Extract
  • GET 2020. Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system. Extract
  • GET 2020. Natural Products as Potential Leads Against Coronaviruses: Could They be Encouraging Structural Models Against SARS-CoV-2? Extract
  • GET 2020. Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China. Extract
  • GET 2020. Overwhelming COVID-19 Clinical Trials: Call for Prospective Meta-Analyses. Extract
  • GET 2020. Battling COVID-19: using old weapons for a new enemy. Extract
  • GET 2020. Potential specific therapies in COVID-19. Extract
  • GET 2020. Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients. Extract
  • GET 2020. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Extract
GET 2020. Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19). Extract
  • GET 2020. Promoting Better Clinical Trials and Drug Information as Public Health Interventions for the COVID-19 Emergency in Italy. Extract
  • GET 2020. Overview of therapeutic drug research for COVID-19 in China. Extract
GET 2020. A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19. Extract
  • GET 2020. Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19. Extract
  • GET 2020. A prospect on the use of antiviral drugs to control local outbreaks of COVID-19. Extract
GET 2020. Literature-based review of the drugs used for the treatment of COVID-19. Extract
  • GET 2020. Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy. Extract
  • GET 2020. Immune checkpoint blockade: releasing the breaks or a protective barrier to COVID-19 severe acute respiratory syndrome? Extract
  • GET 2020. Treatment of Covid19 - Repurposing drugs commonly used in dermatology. Extract
  • GET 2020. The broad-spectrum antiviral recommendations for drug discovery against COVID-19. Extract
  • GET 2020. Discovering small-molecule therapeutics against SARS-CoV-2. Extract
  • GET 2020. Current and future therapeutical approaches for COVID-19. Extract
  • GET 2020. Steps towards COVID-19 suppression. Extract
  • GET 2020. Antiretroviral HIV drugs in COVID-19 research: promises and risks. An opinion piece. Extract
GET 2020. Application of CRISPR/Cas9 to human-induced pluripotent stem cells: from gene editing to drug discovery. Extract
  • GET 2020. Vesicular drug-delivery systems as theranostics in COVID-19. Extract
  • GET 2020. Tackling SARS-CoV-2: proposed targets and repurposed drugs. Extract
  • GET 2020. Can artificial intelligence identify effective COVID-19 therapies? Extract
GET 2020. RNA to the rescue: RNA is one of the most promising targets for drug development given its wide variety of uses. Extract
  • GET 2020. COVID-19 and the Drug Repurposing Tsunami. Extract
  • GET 2020. Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities. Extract
  • GET 2020. Can nanotechnology help in the fight against COVID-19? Extract
GET 2020. Cellular Nanosponges Inhibit SARS-CoV-2 Infectivity. Extract
  • GET 2020. Repositioning of 8565 Existing Drugs for COVID-19. Extract
  • GET 2020. Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19). Extract
  • GET 2020. Targeting infectious Coronavirus Disease 2019 (COVID-19) with Artificial Intelligence (AI) applications: Evidence based opinion. Extract
GET 2020. Statistical Issues and Lessons Learned from COVID-19 Clinical Trials with Lopinavir-Ritonavir and Remdesivir. Extract
  • GET 2020. Potential effectiveness and safety of antiviral agents in children with coronavirus disease 2019: a rapid review and meta-analysis. Extract
  • GET 2020. Pharmacological development of the potential adjuvant therapeutic agents against coronavirus disease 2019. Extract
  • GET 2020. Clinical pharmacology considerations for developing small molecule treatments for COVID-19. Extract
GET 2020. Molecular Targets in the Chemotherapy of Coronavirus Infection. Extract
  • GET 2020. Repurposing old drugs as antiviral agents for coronaviruses. Extract
  • GET 2020. COVID-19 treatment: Combining anti-inflammatory and antiviral therapeutics using a network-based approach. Extract
  • GET 2020. Weathering the Cytokine Storm in COVID-19: Therapeutic Implications. Extract
  • GET 2020. Off-label therapy targeting pathogenic inflammation in COVID-19. Extract
GET 2020. Current pharmacological treatments for SARS-COV-2: A narrative review. Extract
  • GET 2020. Repurposed GI Drugs in the Treatment of COVID-19. Extract
  • GET 2020. Prevention of COVID-19 by drug repurposing: rationale from drugs prescribed for mental disorders. Extract
  • GET 2020. An evidence mapping and analysis of registered COVID-19 clinical trials in China. Extract
  • GET 2020. Drug treatment of coronavirus disease 2019 (COVID-19) in China. Extract
  • GET 2020. Potential protective and therapeutic role of immune checkpoint inhibitors against viral infections and COVID-19. Extract
  • GET 2020. Characteristics of registered clinical trials assessing treatments for COVID-19: a cross-sectional analysis. Extract
GET 2020. Combating sars-cov-2 through lipoxins, proteasome, caveolin and nuclear factor-kappab pathways in non-pregnant and pregnant populations. Extract
  • GET 2020. Metabolomics to Predict Antiviral Drug Efficacy in COVID-19. Extract
  • GET 2020. Predicting Human Microbe-Drug Associations via Graph Convolutional Network with Conditional Random Field. Extract
  • GET 2020. COVID-19 pharmacologic treatments for children: research priorities and approach to pediatric studies. Extract
  • GET 2020. Structural Biology Aids the Research of New Anti-COVID-19 Drugs. Extract
  • GET 2020. Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARSCoV-2 and other acute viral infections: a systematic review and meta-analysis. Extract
  • GET 2020. Potential Treatments for SARS-CoV-2 Infection. Extract
  • GET 2020. The critical role of futility analysis in the pursuit of effective treatments for COVID-19. Extract
  • GET 2020. Review of trials currently testing treatment and prevention of COVID-19. Extract
  • GET 2020. Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients. Extract
  • GET 2020. COVID 19 therapies and anti-cancer drugs: A systematic review of recent literature. Extract
GET 2020. Possible therapeutic agents for COVID-19: a comprehensive review. Extract
  • GET 2020. Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments. Extract
  • GET 2020. Considerations for interactions of drugs used for the treatment of COVID-19 with anti-cancer treatments. Extract
  • GET 2020. Systematic Review and Meta-Analysis of the Efficacy of Nanoscale Materials Against Coronaviruses-Possible Potential Antiviral Agents for SARS-CoV-2. Extract
  • GET 2020. A review of potential treatments to date in COVID-19 patients according to the stage of the disease. Extract
  • GET 2020. Emerging Pharmaceutical Treatments of Novel COVID-19: A Review. Extract
  • GET 2020. COVID-19: A Review of Emerging Preventative Vaccines and Treatment Strategies. Extract
  • GET 2020. Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies. Extract
  • GET 2020. Empiric Therapies for COVID-19: Destined to Fail by Ignoring the Lessons of History. Extract
  • GET 2020. nCOV-19 peptides mass fingerprinting identification, binding, and blocking of inhibitors flavonoids and anthraquinone of Moringa oleifera and hydroxychloroquine. Extract
  • GET 2020. Biologics and Small Molecules in the Treatment of COVID-19. Extract
  • GET 2020. A Comprehensive Analysis of Clinical Trials in the COVID-19 Pandemic Era. Extract
  • GET 2020. The challenging pathway towards the identification of SARS-CoV-2/COVID-19 therapeutics. Extract
  • GET 2020. SARS-COV-2 and biomimetics: What saves the planet will save our health. Extract
  • GET 2020. COVID-19 Clinical Research. Extract
  • GET 2020. Clinical trials for the prevention and treatment of COVID-19: current state of play. Extract
  • GET 2020. Emerging pharmacotherapy for COVID-19. Extract
  • GET 2020. Characteristics of COVID-19 Clinical Trials in China Based on the Registration Data on ChiCTR and ClinicalTrials.gov. Extract
  • GET 2020. Existing Drugs Might Treat COVID-19. Extract
  • GET 2020. Fight against novel coronavirus: A perspective of medicinal chemists. Extract
  • GET 2020. Fighting the Host Reaction to SARS-COv-2 in Critically Ill Patients: The Possible Contribution of Off-Label Drugs. Extract
  • GET 2020. [Comment] Treatment strategies to fight the new coronavirus SARS-CoV-2: A challenge for a Rubik's Cube solver. Extract
  • GET 2020. EML webinar overview: Simulation-assisted discovery of membrane targeting nanomedicine. Extract
  • GET 2020. Investigational Therapies for the Treatment of COVID-19: Updates from Ongoing Clinical Trials. Extract
  • GET 2020. Covid-19 chemoprophylaxis: Ethics of prevention based on anecdotal evidence. Extract
  • GET 2020. Could Coronavirus Disease 2019 (COVID-19) Render Natural Immunity to Re-infections? A Spotlight on the Therapeutic Pipeline. Extract
  • GET 2020. Current global vaccine and drug efforts against COVID-19: Pros and cons of bypassing animal trials. Extract
  • GET 2020. The potential role of nanomedicine on COVID-19 therapeutics. Extract
  • GET 2020. Targeting inflammation and cytokine storm in COVID-19. Extract
  • GET 2020. More than 80 clinical trials launch to test coronavirus treatments. Extract
GET 2020. "Monoclonal-Type" Plastic Antibodies for COVID-19 Treatment: What Is the Idea? Extract
  • GET 2020. Vaccines and Therapies in Development for SARS-CoV-2 Infections. Extract
  • GET 2020. Therapien gegen COVID-19 - ein Update : SARS-CoV-2-Pandemie. Extract
  • GET 2020. Practice considerations on the use of investigational anti-COVID-19 medications: Dosage, administration and monitoring. Extract
  • GET 2020. Critical Need for Implementation of Clinical Pharmacology Principles in Developing Drugs for the Treatment or Prevention of COVID-19. Extract
  • GET 2020. Buying time: Drug repurposing to treat the host in COVID-19H. Extract
GET 2020. Host transcriptome-guided drug repurposing for COVID-19 treatment: a meta-analysis based approach. Extract
GET 2020. Possible Old Drugs for Repositioning in COVID-19 Treatment: Combating Cytokine Storms from Haloperidol to Anti-interleukin Agents. Extract
  • GET 2020. SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries. Extract
  • GET 2020. Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection. Extract
  • GET 2020. COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking. Extract
  • GET 2020. Potential Antiviral Options against SARS-CoV-2 Infection. Extract
  • GET 2020. Vaccines and Drug Therapeutics to Lock Down Novel Coronavirus Disease 2019 (COVID-19): A Systematic Review of Clinical Trials. Extract
  • GET 2020. Structural Basis of the SARS-CoV-2/SARS-CoV Receptor Binding and Small-Molecule Blockers as Potential Therapeutics. Extract
  • GET 2020. Harnessing resolving-based therapeutics to treat pulmonary viral infections: What can the future offer to COVID-19? Extract
  • GET 2020. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19? Extract
  • GET 2020. Sars-cov-2 host entry and replication inhibitors from Indian ginseng: an in-silico approach. Extract
  • GET 2020. A sugar-coated strategy to treat a rare neurologic disease provides a blueprint for a decoy glycan therapeutic and a potential vaccine for CoViD-19: An Editorial Highlight for "Selective inhibition of anti-MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer"on https://doi.org/10.1111/jnc.15021. Extract
  • GET 2020. Recent advances in influenza vaccines. Extract
  • GET 2020. Screening and druggability analysis of some plant metabolites against SARS-CoV-2: An integrative computational approach. Extract
  • GET 2020. Evaluation of the Inhibitory Activities of COVID-19 of Melaleuca cajuputi Oil Using Docking Simulation. Extract
  • GET 2020. Natural compounds from Clerodendrum spp. as possible therapeutic candidates against SARS-CoV-2: An in silico investigation. Extract
  • GET 2020. Computational investigation on Andrographis paniculata phytochemicals to evaluate their potency against SARS-CoV-2 in comparison to known antiviral compounds in drug trials. Extract
  • GET 2020. Saxifraga spinulosa-Derived Components Rapidly Inactivate Multiple Viruses Including SARS-CoV-2. Extract
  • GET 2020. Deceiving SARS-CoV-2 molecular-tropism clues - A combinational contemporary strategy. Extract
  • GET 2020. Herbs that might be effective for the management of COVID-19: A bioinformatics analysis on anti-tyrosine kinase property. Extract
  • GET 2020. Squalene-based multidrug nanoparticles for improved mitigation of uncontrolled inflammation in rodents. Extract
  • GET 2020. DREAM-in-CDM Approach and Identification of a New Generation of Anti-inflammatory Drugs Targeting mPGES-1. Extract
  • GET 2020. Interaction of certain monoterpenoid hydrocarbons with the receptor binding domain of 2019 novel coronavirus (2019-nCoV), transmembrane serine protease 2 (TMPRSS2), cathepsin B, and cathepsin L (CatB/L) and their pharmacokinetic properties. Extract
Meine Werkzeuge
Namensräume
Varianten
Aktionen
Navigation
Werkzeuge